14,625 results match your criteria Heart-Lung Transplantation


Transfer of donor anti-HLA antibody expression to multiple transplant recipients- a potential variant of the Passenger Lymphocyte Syndrome?

Am J Transplant 2019 Jan 17. Epub 2019 Jan 17.

Lung Transplant Service, Alfred Hospital, Melbourne, Australia.

Antibody mediated rejection (AMR), whereby transplant recipient B cells and/or plasma cells produce allo-reactive anti-human leukocyte antigen (HLA) antibodies, negatively influences transplant outcomes and is a major contributor to graft loss. An early humoral immune response is suggested by the production of anti-HLA donor-specific antibodies (DSA) that can be measured using solid phase assays. We report the early post-transplant co-existence of a shared anti-HLA antibody profile in five solid organ transplant recipients who received organs from the same donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15262DOI Listing
January 2019

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma.

J Clin Oncol 2019 Jan 17:JCO1800685. Epub 2019 Jan 17.

City of Hope, Los Angeles, CA.

Purpose: Single-cycle melphalan 200 mg/m and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression.

Patients And Methods: Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00685DOI Listing
January 2019

End of life for patients with left ventricular assist devices: Insights from INTERMACS.

J Heart Lung Transplant 2018 Dec 15. Epub 2018 Dec 15.

Section of Advanced Heart Failure and Transplantation, Division of Cardiology, Department of Medicine; Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado School of Medicine, Aurora, Colorado, USA.

Background: Trial and registry data have reported mortality rates and causes of death in patients with left ventricular assist devices (LVADs); however, a more granular description is needed of end of life, including location of death and quality of life (QOL), to better guide expectations and care.

Methods: To identify where patients with an LVAD died, characterize QOL before death, and cause of death over time, we evaluated patients in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) implanted with a continuous-flow LVAD.

Results: From 18,733 patients implanted with an LVAD during the period 2008 to 2016, 4,916 patients were known to have died, of whom 98% had a recorded location of death. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10532498183178
Publisher Site
http://dx.doi.org/10.1016/j.healun.2018.12.008DOI Listing
December 2018
1 Read

Feasibility of lung microdialysis to assess metabolism during clinical ex vivo lung perfusion.

J Heart Lung Transplant 2018 Dec 20. Epub 2018 Dec 20.

Department of Medical and Surgical Science and Biotechnologies, Sapienza University of Rome, Rome, Italy.

Background: Lung metabolism during ex vivo lung perfusion (EVLP) is increasingly studied. Microdialysis (MD) allows metabolic monitoring by sampling parenchymal interstitial fluid. This study investigated lung metabolism using MD during EVLP and evaluated whether microdialysate metabolites could improve selection and discriminate outcome of donor lungs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.12.015DOI Listing
December 2018

Validation of the International Society for Heart and Lung Transplantation primary graft dysfunction instrument in heart transplantation.

J Heart Lung Transplant 2018 Dec 18. Epub 2018 Dec 18.

Ted Rogers Centre for Heart Research, Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.

Background: In 2014, the International Society for Heart and Lung Transplantation (ISHLT) developed a classification instrument for left ventricular (LV) and isolated right ventricular (RV) primary graft dysfunction post‒heart transplant. The instrument classifies LV-PGD as mild, moderate, or severe. In this study, we evaluated the predictive validity of this instrument. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.12.007DOI Listing
December 2018

Montelukast in chronic lung allograft dysfunction after lung transplantation.

J Heart Lung Transplant 2018 Dec 6. Epub 2018 Dec 6.

Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium; Department of Chronic Diseases, Metabolism & Ageing, Division of Respiratory Diseases, KU Leuven, Leuven, Belgium.

Background: Chronic lung allograft dysfunction (CLAD) is a major cause of post‒lung transplant mortality, with limited medical treatment options. In this study we assessed the association of montelukast treatment with pulmonary function and outcome in lung transplant recipients with progressive CLAD.

Methods: We performed a retrospective study of all lung transplant recipients transplanted between July 1991 and December 2016 at our center and who were treated for at least 3 months with montelukast for progressive CLAD, despite at least 3 months of prior azithromycin therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.11.014DOI Listing
December 2018

Hypothermic perfusion of donor heart with a preservation solution supplemented by mesenchymal stem cells.

J Heart Lung Transplant 2018 Dec 6. Epub 2018 Dec 6.

Department of Cardiac Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Background: Heart transplantation is the definitive treatment for end-stage heart failure. A shortage of donor hearts forced transplant programs to accept older donors and longer ischemic times. Previous studies have suggested that administration of mesenchymal stem cells (MSCs) or their conditioned medium (CM) protects the heart against ischemia/reperfusion injury (IRI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.12.003DOI Listing
December 2018

International Society of Heart and Lung Transplantation position statement on the role of right heart catheterization in the management of heart transplant recipients.

J Heart Lung Transplant 2018 Dec 21. Epub 2018 Dec 21.

The Pauley Heart Center, Virginia Commonwealth University Medical Center, Richmond, Virginia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.12.009DOI Listing
December 2018

State of the art: Evaluation and prognostication of myocarditis using cardiac MRI.

J Magn Reson Imaging 2019 Jan 13. Epub 2019 Jan 13.

Department of Cardiology, Barbara and Donald Zucker School of Medicine at Hofstra Northwell, Manhasset, New York, USA.

Myocarditis encompasses both primary and secondary processes causing inflammation of the myocardium. Viral infections are a common secondary cause of myocarditis with important clinical relevance. Viral myocarditis has a varied clinical presentation, potentially resulting in significant morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26611DOI Listing
January 2019

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Authors:
Clotilde Théry Kenneth W Witwer Elena Aikawa Maria Jose Alcaraz Johnathon D Anderson Ramaroson Andriantsitohaina Anna Antoniou Tanina Arab Fabienne Archer Georgia K Atkin-Smith D Craig Ayre Jean-Marie Bach Daniel Bachurski Hossein Baharvand Leonora Balaj Shawn Baldacchino Natalie N Bauer Amy A Baxter Mary Bebawy Carla Beckham Apolonija Bedina Zavec Abderrahim Benmoussa Anna C Berardi Paolo Bergese Ewa Bielska Cherie Blenkiron Sylwia Bobis-Wozowicz Eric Boilard Wilfrid Boireau Antonella Bongiovanni Francesc E Borràs Steffi Bosch Chantal M Boulanger Xandra Breakefield Andrew M Breglio Meadhbh Á Brennan David R Brigstock Alain Brisson Marike Ld Broekman Jacqueline F Bromberg Paulina Bryl-Górecka Shilpa Buch Amy H Buck Dylan Burger Sara Busatto Dominik Buschmann Benedetta Bussolati Edit I Buzás James Bryan Byrd Giovanni Camussi David Rf Carter Sarah Caruso Lawrence W Chamley Yu-Ting Chang Chihchen Chen Shuai Chen Lesley Cheng Andrew R Chin Aled Clayton Stefano P Clerici Alex Cocks Emanuele Cocucci Robert J Coffey Anabela Cordeiro-da-Silva Yvonne Couch Frank Aw Coumans Beth Coyle Rossella Crescitelli Miria Ferreira Criado Crislyn D'Souza-Schorey Saumya Das Amrita Datta Chaudhuri Paola de Candia Eliezer F De Santana Olivier De Wever Hernando A Del Portillo Tanguy Demaret Sarah Deville Andrew Devitt Bert Dhondt Dolores Di Vizio Lothar C Dieterich Vincenza Dolo Ana Paula Dominguez Rubio Massimo Dominici Mauricio R Dourado Tom Ap Driedonks Filipe V Duarte Heather M Duncan Ramon M Eichenberger Karin Ekström Samir El Andaloussi Celine Elie-Caille Uta Erdbrügger Juan M Falcón-Pérez Farah Fatima Jason E Fish Miguel Flores-Bellver András Försönits Annie Frelet-Barrand Fabia Fricke Gregor Fuhrmann Susanne Gabrielsson Ana Gámez-Valero Chris Gardiner Kathrin Gärtner Raphael Gaudin Yong Song Gho Bernd Giebel Caroline Gilbert Mario Gimona Ilaria Giusti Deborah Ci Goberdhan André Görgens Sharon M Gorski David W Greening Julia Christina Gross Alice Gualerzi Gopal N Gupta Dakota Gustafson Aase Handberg Reka A Haraszti Paul Harrison Hargita Hegyesi An Hendrix Andrew F Hill Fred H Hochberg Karl F Hoffmann Beth Holder Harry Holthofer Baharak Hosseinkhani Guoku Hu Yiyao Huang Veronica Huber Stuart Hunt Ahmed Gamal-Eldin Ibrahim Tsuneya Ikezu Jameel M Inal Mustafa Isin Alena Ivanova Hannah K Jackson Soren Jacobsen Steven M Jay Muthuvel Jayachandran Guido Jenster Lanzhou Jiang Suzanne M Johnson Jennifer C Jones Ambrose Jong Tijana Jovanovic-Talisman Stephanie Jung Raghu Kalluri Shin-Ichi Kano Sukhbir Kaur Yumi Kawamura Evan T Keller Delaram Khamari Elena Khomyakova Anastasia Khvorova Peter Kierulf Kwang Pyo Kim Thomas Kislinger Mikael Klingeborn David J Klinke Miroslaw Kornek Maja M Kosanović Árpád Ferenc Kovács Eva-Maria Krämer-Albers Susanne Krasemann Mirja Krause Igor V Kurochkin Gina D Kusuma Sören Kuypers Saara Laitinen Scott M Langevin Lucia R Languino Joanne Lannigan Cecilia Lässer Louise C Laurent Gregory Lavieu Elisa Lázaro-Ibáñez Soazig Le Lay Myung-Shin Lee Yi Xin Fiona Lee Debora S Lemos Metka Lenassi Aleksandra Leszczynska Isaac Ts Li Ke Liao Sten F Libregts Erzsebet Ligeti Rebecca Lim Sai Kiang Lim Aija Linē Karen Linnemannstöns Alicia Llorente Catherine A Lombard Magdalena J Lorenowicz Ákos M Lörincz Jan Lötvall Jason Lovett Michelle C Lowry Xavier Loyer Quan Lu Barbara Lukomska Taral R Lunavat Sybren Ln Maas Harmeet Malhi Antonio Marcilla Jacopo Mariani Javier Mariscal Elena S Martens-Uzunova Lorena Martin-Jaular M Carmen Martinez Vilma Regina Martins Mathilde Mathieu Suresh Mathivanan Marco Maugeri Lynda K McGinnis Mark J McVey David G Meckes Katie L Meehan Inge Mertens Valentina R Minciacchi Andreas Möller Malene Møller Jørgensen Aizea Morales-Kastresana Jess Morhayim François Mullier Maurizio Muraca Luca Musante Veronika Mussack Dillon C Muth Kathryn H Myburgh Tanbir Najrana Muhammad Nawaz Irina Nazarenko Peter Nejsum Christian Neri Tommaso Neri Rienk Nieuwland Leonardo Nimrichter John P Nolan Esther Nm Nolte-'t Hoen Nicole Noren Hooten Lorraine O'Driscoll Tina O'Grady Ana O'Loghlen Takahiro Ochiya Martin Olivier Alberto Ortiz Luis A Ortiz Xabier Osteikoetxea Ole Østergaard Matias Ostrowski Jaesung Park D Michiel Pegtel Hector Peinado Francesca Perut Michael W Pfaffl Donald G Phinney Bartijn Ch Pieters Ryan C Pink David S Pisetsky Elke Pogge von Strandmann Iva Polakovicova Ivan Kh Poon Bonita H Powell Ilaria Prada Lynn Pulliam Peter Quesenberry Annalisa Radeghieri Robert L Raffai Stefania Raimondo Janusz Rak Marcel I Ramirez Graça Raposo Morsi S Rayyan Neta Regev-Rudzki Franz L Ricklefs Paul D Robbins David D Roberts Silvia C Rodrigues Eva Rohde Sophie Rome Kasper Ma Rouschop Aurelia Rughetti Ashley E Russell Paula Saá Susmita Sahoo Edison Salas-Huenuleo Catherine Sánchez Julie A Saugstad Meike J Saul Raymond M Schiffelers Raphael Schneider Tine Hiorth Schøyen Aaron Scott Eriomina Shahaj Shivani Sharma Olga Shatnyeva Faezeh Shekari Ganesh Vilas Shelke Ashok K Shetty Kiyotaka Shiba Pia R-M Siljander Andreia M Silva Agata Skowronek Orman L Snyder Rodrigo Pedro Soares Barbara W Sódar Carolina Soekmadji Javier Sotillo Philip D Stahl Willem Stoorvogel Shannon L Stott Erwin F Strasser Simon Swift Hidetoshi Tahara Muneesh Tewari Kate Timms Swasti Tiwari Rochelle Tixeira Mercedes Tkach Wei Seong Toh Richard Tomasini Ana Claudia Torrecilhas Juan Pablo Tosar Vasilis Toxavidis Lorena Urbanelli Pieter Vader Bas Wm van Balkom Susanne G van der Grein Jan Van Deun Martijn Jc van Herwijnen Kendall Van Keuren-Jensen Guillaume van Niel Martin E van Royen Andre J van Wijnen M Helena Vasconcelos Ivan J Vechetti Tiago D Veit Laura J Vella Émilie Velot Frederik J Verweij Beate Vestad Jose L Viñas Tamás Visnovitz Krisztina V Vukman Jessica Wahlgren Dionysios C Watson Marca Hm Wauben Alissa Weaver Jason P Webber Viktoria Weber Ann M Wehman Daniel J Weiss Joshua A Welsh Sebastian Wendt Asa M Wheelock Zoltán Wiener Leonie Witte Joy Wolfram Angeliki Xagorari Patricia Xander Jing Xu Xiaomei Yan María Yáñez-Mó Hang Yin Yuana Yuana Valentina Zappulli Jana Zarubova Vytautas Žėkas Jian-Ye Zhang Zezhou Zhao Lei Zheng Alexander R Zheutlin Antje M Zickler Pascale Zimmermann Angela M Zivkovic Davide Zocco Ewa K Zuba-Surma

J Extracell Vesicles 2018 23;7(1):1535750. Epub 2018 Nov 23.

Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of Cell Biology, Kraków, Poland.

The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines for the field in 2014. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/20013078.2018.1
Publisher Site
http://dx.doi.org/10.1080/20013078.2018.1535750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322352PMC
November 2018
5 Reads

Heart or heart-lung transplantation for patients with congenital heart disease in England.

Heart 2019 Jan 12. Epub 2019 Jan 12.

Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK.

Background: Increased longevity in patients with congenital heart disease (CHD) is associated with late complications, mainly heart failure, which may not be amenable to redo surgery and become refractory to medical therapy and so, trigger referral for transplantation. We assessed the current role and future prospects of heart and heart-lung transplantation for patients with CHD in England.

Methods: We performed a retrospective analysis of hospital episodes for England for 1997-2015, identifying patients with a CHD code (ICD-10 'Q2xx. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/heartjnl-2018-313984DOI Listing
January 2019
1 Read

Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients.

Front Immunol 2018 19;9:3002. Epub 2018 Dec 19.

Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.

The best treatment for patients with end-stage renal disease is kidney transplantation. Although graft survival rates have improved in the last decades, patients still may lose their grafts partly due to the detrimental effects of donor-specific antibodies (DSA) against human leukocyte antigens (HLA) and to a lesser extent also by antibodies directed against non-HLA antigens expressed on the donor endothelium. Assays to detect anti-HLA antibodies are already in use for many years and have been proven useful for transplant risk stratification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.03002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315148PMC
December 2018

Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®.

Crit Rev Microbiol 2019 Jan 10:1-21. Epub 2019 Jan 10.

at Department of Microbiology and Immunology , Catholic University Leuven , Leuven , Belgium.

Invasive Scedosporium spp. and Lomentospora prolificans infections are an emerging threat in immunocompromised and occasionally in healthy hosts. Scedosporium spp. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/1040841X.2018.1
Publisher Site
http://dx.doi.org/10.1080/1040841X.2018.1514366DOI Listing
January 2019
1 Read

Post-transplant diabetes mellitus in patients with solid organ transplants.

Nat Rev Endocrinol 2019 Jan 8. Epub 2019 Jan 8.

Department of Transplantation Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.

Solid organ transplantation (SOT) is a life-saving procedure and an established treatment for patients with end-stage organ failure. However, transplantation is also accompanied by associated cardiovascular risk factors, of which post-transplant diabetes mellitus (PTDM) is one of the most important. PTDM develops in 10-20% of patients with kidney transplants and in 20-40% of patients who have undergone other SOT. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41574-018-0137-7
Publisher Site
http://dx.doi.org/10.1038/s41574-018-0137-7DOI Listing
January 2019
2 Reads

Extracellular Vesicles Released by Human Induced-Pluripotent Stem Cell-Derived Cardiomyocytes Promote Angiogenesis.

Front Physiol 2018 14;9:1794. Epub 2018 Dec 14.

Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Although cell survival post-transplantation is very low, emerging evidence using stem cell therapy for myocardial repair points toward a primary role of paracrine signaling mechanisms as the basis for improved cardiac function, decreased fibrosis, and increased angiogenesis. Recent studies have demonstrated that extracellular vesicles (EVs) such as exosomes secreted by stem cells stimulate angiogenesis, provide cytoprotection, and modulate apoptosis. However, the angiogenic potential of EVs secreted from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM), a terminally differentiated cell type, has not been elucidated yet. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fphys.2018.01794
Publisher Site
http://dx.doi.org/10.3389/fphys.2018.01794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302004PMC
December 2018
3 Reads

Bone mineral density and osteoporosis in heart transplanted patients: A single-centre retrospective study at Skåne University Hospital in Lund 1988-2016.

Clin Transplant 2019 Jan 7:e13477. Epub 2019 Jan 7.

Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden.

Bone mineral density (BMD) in the lumbar spine and femoral neck, the incidence of osteoporosis, and survival up to 10 years after heart transplantation (HT) were investigated in 169 patients who underwent HT at Skåne University Hospital in Lund, Sweden, 1988-2016. Within the first year post-transplantation, mean (SD) BMD decreased by 3.9% (10. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ctr.13477
Publisher Site
http://dx.doi.org/10.1111/ctr.13477DOI Listing
January 2019
1 Read

Reduced right ventricular output reserve in patients with systemic sclerosis and mildly elevated pulmonary arterial pressures.

Arthritis Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Centre for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.

Objective: The objective of this prospective study was to evaluate right ventricular function and pulmonary arterial compliance (PAC=stroke volume/pulse pressure) at rest and during exercise in patients with systemic sclerosis (SSc) with normal mean pulmonary artery pressures (mPAP) at rest, mildly elevated mPAP (mPAP 21-24mmHg) and manifest pulmonary hypertension (mPAP≥25mmHg).

Methods: Patients with SSc (n=112) underwent clinical assessment and right heart catheterization at rest and during exercise and were divided into three groups according to their resting mPAP values: normal mPAP (≤20mmHg), mildly elevated mPAP (21-24mmHg) and pulmonary hypertension (PH, mPAP ≥25mmHg). Results were compared between groups by ANOVA followed by post-hoc student's t-test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40814DOI Listing
January 2019

A randomized trial of everolimus-based quadruple therapy versus standard triple therapy early after lung transplantation.

Am J Transplant 2019 Jan 7. Epub 2019 Jan 7.

Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, and Children's Hospital of New Jersey, Newark, USA.

Calcineurin inhibitor (CNI) therapy after lung transplantation increases risk of kidney failure. Early everolimus-based quadruple low CNI immunosuppression may improve renal function without compromising efficacy or safety. A prospective, randomized, open-label, 12-month multicenter trial was conducted at eight German sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15251DOI Listing
January 2019

Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.

Br J Haematol 2019 Jan 6. Epub 2019 Jan 6.

Department of Pediatrics, New York Medical College, Valhalla, NY, USA.

Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th-29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15753DOI Listing
January 2019

Multidisciplinary inpatient rehabilitation following heart and/or lung transplantation - examining cohort characteristics and clinical outcomes.

PM R 2019 Jan 4. Epub 2019 Jan 4.

Department of Rehabilitation, St Vincent's Hospital Sydney, NSW, Australia.

Background: Cardiopulmonary transplant is becoming a more common treatment option for advanced heart and/or lung disease. Specialist rehabilitation programs may assist recovery and enhance functional independence following transplant.

Objective: To quantify the outcomes of multidisciplinary inpatient rehabilitation following cardiopulmonary transplant, and describe cohort characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pmrj.12057DOI Listing
January 2019
1 Read

Solid-Organ Transplantation and the Affordable Care Act: Accessibility and Outcomes.

Am Surg 2018 Dec;84(12):1894-1899

The objective of the study is to evaluate the impact of the Affordable Care Act (ACA) on accessibility to solid organ transplant and outcomes. Data source registry: United Network of Organ Sharing database. Patients aged ≥18 years listed for kidney, liver, heart, and lung transplant between years 2010 and 2016 were classified by insurance and status of Medicaid adoption under ACA to evaluate insurance distribution. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Semiquantification of Systemic Venous Admixture During Venovenous Extracorporeal Oxygenation Via Bicaval Double-Lumen Cannula in Critically Ill Patients.

ASAIO J 2018 Dec 28. Epub 2018 Dec 28.

Department of Cardiothoracic Surgery, St George Hospital, Kogarah, New South Wales, Australia.

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is increasingly utilized in acute reversible cases of severe respiratory failure and as a bridge to lung transplantation. Venovenous extracorporeal membrane oxygenation using a bicaval double-lumen cannula (BCDLC) has several advantages over the traditional ECMO configuration; however, it also presents with several unique challenges. The assessment and quantification of venous admixture is difficult due to the specific position of BCDLC within the circulatory system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MAT.0000000000000943DOI Listing
December 2018

Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid.

Bioorg Med Chem 2018 Dec 16. Epub 2018 Dec 16.

Division of Pharmaceutics & Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States; The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, United States; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, United States; The Center for Clinical and Translational Science, The Ohio State University, Columbus, OH 43210, United States; Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, Columbus, OH 43210, United States; Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, United States. Electronic address:

Daratumumab, an FDA approved antibody drug, displays specific targeting ability to abnormal white blood cells overexpressing CD38 and provides efficacious therapy for multiple myeloma. Here, in order to achieve enhanced remission of multiple myeloma, we designed Dara-DM4, antibody drug conjugates (ADCs) by conjugating Daratumumab and DM4 via a disulfide linker. Dara-DM4 showed significantly higher cellular uptake and inhibitory efficacy on MM1S cells that overexpressing CD38 with an IC of 0. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896183162
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2018.12.024DOI Listing
December 2018
4 Reads

[Extracorporeal membrane oxygenation as a bridge to lung transplantation].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2018 Dec;30(12):1167-1172

Department of Intensive Care Unit, Affiliated Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, Jiangsu, China (Xia W, Xu HY); Department of Thoracic Surgery, Affiliated Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, Jiangsu, China (Mao WJ, Chen JY). Corresponding author: Xu Hongyang, Email:

Objective: To evaluate the effect of extracorporeal membrane oxygenation (ECMO) as a bridge to lung transplantation (LTx).

Methods: The clinical data of 18 patients with end-stage lung diseases was retrospectively reviewed, using ECMO as a bridge to LTx in intensive care unit of Affiliated Wuxi People's Hospital from January 2015 to December 2017. Clinical parameters were obtained from these patients, including gender, age, primary disease, preoperative lactate level, preoperative leukocyte, operation modality (unilateral or bilateral), type of ECMO, ECMO support time as a bridge to LTx, ECMO support time after operation, total usage time of ECMO, ECMO associated complications, primary graft dysfunction (PGD), successful ECMO weaning, and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.2095-4352.2018.012.013DOI Listing
December 2018
1 Read

Lung Transplantation for Late-Onset Pulmonary Hypertension in a Patient with Congenital Diaphragmatic Hernia.

European J Pediatr Surg Rep 2018 Jan 26;6(1):e100-e103. Epub 2018 Dec 26.

Department of Neonatal Surgery, Bambino Gesù Children's Hospital, Rome, Italy.

Lung hypoplasia and pulmonary hypertension (PH) in association with congenital diaphragmatic hernia (CDH) may cause fatal respiratory failure. Lung transplantation (Ltx) may represent an option for CDH-related end-stage pulmonary failure. The aim of this study is to report a patient with CDH who underwent Ltx or combined heart-lung transplantation (H-Ltx). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0038-1675377DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306278PMC
January 2018
1 Read

Hematopoietic Deficiency of the Long Non-Coding RNA MALAT1 Promotes Atherosclerosis and Plaque Inflammation.

Circulation 2018 Nov 28. Epub 2018 Nov 28.

Institute for Cardiovascular Regeneration, Goethe University Frankfurt, GERMANY.

Background: The majority of the human genome comprises non-coding sequences, which are in part transcribed as long non-coding RNAs (lncRNAs). LncRNAs exhibit multiple functions including the epigenetic control of gene expression. Here we studied the effect of the lncRNA MALAT1 on atherosclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029015DOI Listing
November 2018
14.430 Impact Factor

Solid organ transplantation after haematopoietic stem cell transplantation in childhood: a multicentric retrospective survey.

Am J Transplant 2018 Dec 26. Epub 2018 Dec 26.

Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt, Frankfurt am Main, Germany.

We report data obtained from a retrospective multicenter pediatric survey on behalf of the European Society for Blood and Marrow Transplantation (EBMT). Information on Solid Organ Transplantation (SOT) performed in pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 were collected in 20 pediatric EBMT Centers (25.6%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15240DOI Listing
December 2018

Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy (POSITIVE Study): The Collaboration and Design of a National Transplant Precision Medicine Program.

Transplant Direct 2018 Dec 27;4(12):e410. Epub 2018 Nov 27.

Division of Cardiology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Background: Despite age-related differences in biology, physiology, and behavior, transplant immunosuppression is not tailored by age. This likely contributes to high graft failure and posttransplant complications. We present the aims, design, and methods of the Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy Study aimed at personalizing posttransplant immunosuppression in children and young adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TXD.0000000000000842DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283088PMC
December 2018

A 24-hour perioperative case study on argatroban use for left ventricle assist device insertion during cardiopulmonary bypass and veno-arterial extracorporeal membrane oxygenation.

Perfusion 2018 Dec 25:267659118813043. Epub 2018 Dec 25.

3 Division of Cardiac Surgery, London Health Sciences Centre, London, Ontario, Canada.

A 44-year-old male with ongoing chest pain and left ventricular ejection fraction <20% was transferred from a peripheral hospital with intra-aortic balloon pump placement following a non-ST-elevation myocardial infarction (STEMI). The patient underwent emergent multi-vessel coronary artery bypass grafting requiring veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) on post-operative day (POD)#9 secondary to cardiogenic shock with biventricular failure. Due to clot formation, an oxygenator change-out was necessary shortly after initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0267659118813043DOI Listing
December 2018
4 Reads
1.083 Impact Factor

Capillary density in right ventricular myocardium in congenital heart disease.

J Heart Lung Transplant 2018 Dec 7. Epub 2018 Dec 7.

Paris-Saclay University, School of Medicine, Kremlin-Bicêtre, France; Surgical Research Lab; Department of Thoracic and Vascular Surgery and Heart‒Lung Transplantation, DHU Thorax Innovation, Marie Lannelongue Hospital, Le Plessis Robinson, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.12.001DOI Listing
December 2018

Utilization of organs to pediatric heart transplant recipients.

J Heart Lung Transplant 2018 Dec 14. Epub 2018 Dec 14.

Swisstransplant, the Swiss National Foundation for Organ Donation and Transplantation, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.healun.2018.12.005DOI Listing
December 2018
1 Read

The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach.

Am Heart J 2018 Nov 24;208:91-99. Epub 2018 Nov 24.

Department of Cardiology, Erasmus Medical Centre, Rotterdam, the Netherlands. Electronic address:

Background: This study aimed to investigate the prognostic value of six different biomarkers in patients with pulmonary hypertension (PH) and to explore whether a multi-biomarker approach can contribute to a better risk stratification.

Methods: In this prospective study, patients with PH were included at the day of the diagnostic right heart catheterization between May 2012 and October 2016. Venous blood sampling included; NT-proBNP, high sensitive troponin-T, high sensitive CRP, galectin-3, red blood cell distribution width and eGFR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ahj.2018.11.001DOI Listing
November 2018
1 Read

MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Leuk Res 2019 Jan 4;76:70-75. Epub 2018 Dec 4.

Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Germline mutation in GATA2 can lead to GATA2 deficiency characterized by a complex multi-system disorder that can present with many manifestations including variable cytopenias, bone marrow failure, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), and severe immunodeficiency. Penetrance and expressivity within families is often variable. There is a spectrum of bone marrow disease in symptomatic cytopenic patients ranging from hypocellular marrows without overt dysplasia to those with definitive MDS, AML, or chronic myelomonocytic leukemia. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.013DOI Listing
January 2019
5 Reads

Syndecan-1 as an independent risk factor for the incidence of adverse cardiovascular events in patients having stage C and D heart failure with non-ischemic dilated cardiomyopathy.

Clin Chim Acta 2018 Dec 19;490:63-68. Epub 2018 Dec 19.

Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing 100029, China. Electronic address:

Background: Patients with heart failure (HF) having non-ischemic dilated cardiomyopathy (DCM) have high mortality rates. Syndecan-1 is reportedly associated with cardiac fibrosis and inflammation. This study explored the role of syndecan-1 in patients with non-ischemic DCM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2018.12.022DOI Listing
December 2018
2 Reads

Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus.

Clin Transplant 2018 Dec 21:e13466. Epub 2018 Dec 21.

Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Background: Despite a survival benefit from transplantation and acceptable outcomes, patients with human immunodeficiency virus (HIV+) face barriers to kidney transplantation. Little is known about the acceptance or decline of organ offers on their behalf because waitlist registry data do not include HIV serostatus.

Methods: We performed a retrospective cohort study using match run data from the Organ Procurement and Transplantation Network, including every kidney offer from May 1, 2007, to July 3, 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ctr.13466DOI Listing
December 2018

Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.

Transplant Proc 2018 Dec 7;50(10):3739-3747. Epub 2018 Sep 7.

Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.

Background And Objectives: Heart and lung transplantation is a high-risk procedure, requiring intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a CD52-specific monoclonal antibody, is increasingly used for induction therapy compared with conventional agents. However, there has been no systematic review comparing its efficacy with traditional therapeutic drugs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00411345183098
Publisher Site
http://dx.doi.org/10.1016/j.transproceed.2018.08.018DOI Listing
December 2018
5 Reads

Acute Cellular Rejection and Infection Rates in Alemtuzumab vs Traditional Induction Therapy Agents for Lung and Heart Transplantation: A Systematic Review and Meta-analysis.

Transplant Proc 2018 Dec 7;50(10):3723-3731. Epub 2018 Sep 7.

Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China. Electronic address:

Background And Objectives: Heart and lung transplantation is a high-risk procedure requiring intensive immunosuppressive therapy for preventing organ rejection. Alemtuzumab, a CD52-specific monoclonal antibody, is increasingly used for induction therapy compared with conventional agents. However, there has been no systematic review comparing its efficacy with traditional therapeutic drugs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00411345183118
Publisher Site
http://dx.doi.org/10.1016/j.transproceed.2018.08.044DOI Listing
December 2018
10 Reads

Operative Techniques and Pitfalls in Donor Heart-Lung Procurement.

Transplant Proc 2018 Dec 22;50(10):3111-3112. Epub 2018 Jun 22.

Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA. Electronic address:

Background: Heart-lung transplantation is a well-established therapeutic modality for concomitant end-stage heart and lung failure. With growing organ scarcity, the rates of these transplants are declining, and center experience is waning.

Methods: With over 35 years of experience performing heart-lung transplantation, we describe our procurement protocol herein, as well as offer suggestions to avoid potential pitfalls in order to ensure technical excellence in harvesting these valuable grafts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2018.06.009DOI Listing
December 2018

Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis.

J Am Heart Assoc 2018 Dec;7(23):e008251

1 Department of Medicine and Therapeutics Faculty of Medicine The Chinese University of Hong Kong Hong Kong, SAR.

Background Although frailty has been associated with increased risks for hospitalization and mortality in chronic heart failure, the precise average effect remains uncertain. We performed a systematic review and meta-analysis to summarize the hazards for mortality and incident hospitalization in patients with heart failure and frailty compared with those without frailty and explored the heterogeneity underlying the effect size estimates. Methods and Results MEDLINE , EMBASE, and Cochrane databases were queried for articles published between January 1966 and March 2018. Read More

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/JAHA.117.008251
Publisher Site
http://dx.doi.org/10.1161/JAHA.117.008251DOI Listing
December 2018
1 Read

Critical role of C5a in sickle cell disease.

Am J Hematol 2018 Dec 19. Epub 2018 Dec 19.

Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.

Innate immune complement activation may contribute to sickle cell disease (SCD) pathogenesis. Ischemia-reperfusion physiology is a key component of the inflammatory and vaso-occlusive milieu in SCD and is associated with complement activation. C5a is an anaphylatoxin, a potent pro-inflammatory mediator that can activate leukocytes, platelets, and endothelial cells, all of which play a role in vaso-occlusion. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25384
Publisher Site
http://dx.doi.org/10.1002/ajh.25384DOI Listing
December 2018
12 Reads

Tissue-Engineered Grafts from Human Decellularized Extracellular Matrices: A Systematic Review and Future Perspectives.

Int J Mol Sci 2018 Dec 18;19(12). Epub 2018 Dec 18.

Department of Neuroscience, Section of Human Anatomy, University of Padova, Via A. Gabelli 65, 35121 Padova, Italy.

Tissue engineering and regenerative medicine involve many different artificial and biologic materials, frequently integrated in composite scaffolds, which can be repopulated with various cell types. One of the most promising scaffolds is decellularized allogeneic extracellular matrix (ECM) then recellularized by autologous or stem cells, in order to develop fully personalized clinical approaches. Decellularization protocols have to efficiently remove immunogenic cellular materials, maintaining the nonimmunogenic ECM, which is endowed with specific inductive/differentiating actions due to its architecture and bioactive factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19124117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321114PMC
December 2018
2.862 Impact Factor

Risk of lung cancer in lung transplant recipients in the United States.

Am J Transplant 2018 Dec 18. Epub 2018 Dec 18.

Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.

Lung transplant recipients have an increased risk of lung cancer that is poorly understood. Prior studies are largely descriptive and single-center, and have not examined risk factors or outcomes in this population. This registry-linkage study utilized matched transplant and cancer registry data from 17 US states/regions during 1987-2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15181DOI Listing
December 2018
5.683 Impact Factor

Recipient working status is independently associated with outcomes in heart and lung transplantation.

Clin Transplant 2018 Dec 13:e13462. Epub 2018 Dec 13.

Division of Cardiac Surgery, University of California, Los Angeles, California.

Employment status may capture elements of patients' physical strength, mental resilience, and socioeconomic status to better prognosticate transplant outcomes. This study characterized the effect of working status on thoracic transplant outcomes by evaluating the United Network for Organ Sharing registry for adult lung or heart transplants from 2005 to 2016. Kaplan-Meier estimates illustrated 5-year and 10-year survival by working status at transplant, while multivariable Cox proportional hazards regressions controlled for baseline differences, including functional and socioeconomic status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ctr.13462DOI Listing
December 2018

Prolongation of allograft survival by passenger donor regulatory T cells.

Am J Transplant 2018 Dec 12. Epub 2018 Dec 12.

Department of Surgery, University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom.

Tissue resident lymphocytes are present within many organs, and are presumably transferred at transplantation, but their impact upon host immunity is unclear. Here we examine whether transferred donor natural regulatory CD4 T cells (nT-regs) inhibit host alloimmunity and prolong allograft survival. Transfer of donor-strain lymphocytes was first assessed by identifying circulating donor-derived CD4 T cells in 21 consecutive human lung transplant recipients, with three patterns of chimerism apparent: transient; intermediate; and persistent (detectable for up to 6 weeks, 6 months, and beyond one year, respectively). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15212DOI Listing
December 2018

Practice Variation, Costs and Outcomes Associated with the Use of Inhaled Nitric Oxide in Pediatric Heart Transplant Recipients.

Pediatr Cardiol 2018 Dec 13. Epub 2018 Dec 13.

Department of Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Vanderbilt University, 2200 Children's Way, Suite 5230 DOT, Nashville, TN, 37232-9119, USA.

Right ventricular (RV) failure is a potentially fatal complication following heart transplantation (HTx). Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that is used to decrease pulmonary vascular resistance immediately post-HTx to reduce the risk of RV failure. The aim of this study was to describe utilization patterns, costs, and outcomes associated with post-transplant iNO use in children. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00246-018-2042-1
Publisher Site
http://dx.doi.org/10.1007/s00246-018-2042-1DOI Listing
December 2018
6 Reads

Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity.

Mol Ther Methods Clin Dev 2018 Dec 25;11:143-154. Epub 2018 Oct 25.

Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892, USA.

Gene therapies using integrating retrovirus vectors to modify hematopoietic stem and progenitor cells have shown great promise for the treatment of immune system and hematologic diseases. However, activation of proto-oncogenes via insertional mutagenesis has resulted in the development of leukemia. We have utilized cellular bar coding to investigate the impact of different vector designs on the clonal behavior of hematopoietic stem and progenitor cells (HSPCs) during expansion, as a quantitative surrogate assay for genotoxicity in a non-human primate model with high relevance for human biology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtm.2018.10.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258888PMC
December 2018

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension.

Eur Respir J 2018 Dec 13. Epub 2018 Dec 13.

Dept of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.

Intensive care of patients with pulmonary hypertension (PH) and right-sided heart failure includes treatment of factors causing or contributing to heart failure, careful fluid management, and strategies to reduce ventricular afterload and improve cardiac function. Extracorporeal membrane oxygenation (ECMO) should be considered in distinct situations, especially in candidates for lung transplantation (bridge to transplant) or, occasionally, in patients with a reversible cause of right-sided heart failure (bridge to recovery). ECMO should not be used in patients with end-stage disease without a realistic chance for recovery or for transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.01906-2018DOI Listing
December 2018
1 Read

Risk stratification and medical therapy of pulmonary arterial hypertension.

Eur Respir J 2018 Dec 13. Epub 2018 Dec 13.

Cardiovascular Medicine, The University of Michigan, Ann Arbor, MI, USA.

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.01889-2018DOI Listing
December 2018
8 Reads

Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.

Respiration 2018 Dec 13:1-12. Epub 2018 Dec 13.

Department of Pulmonary Disease, Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam, The Netherlands.

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with a dismal survival rate of only 3 years and no curative pharmacological therapy. The recent approval of 2 anti-fibrotic drugs (nintedanib and pirfenidone) that slow disease progression has provided some hope for patients. However, effectively managing anti-fibrotic treatment can be a challenge due to tolerability issues, the presence of pulmonary and extra-pulmonary comorbidities, and the need for concomitant medications in many patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495046DOI Listing
December 2018